Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]

Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]

Bibliographic Details
Main Authors: Anuja Pandit, Nirav Bhalani, B.L. Shashi Bhushan, Parshottam Koradia, Shweta Gargiya, Vinay Bhomia, Kevinkumar Kansagra
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:International Journal of Infectious Diseases
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971221005191

Internet

http://www.sciencedirect.com/science/article/pii/S1201971221005191

Similar Items